PMID- 19085803
OWN - NLM
STAT- MEDLINE
DCOM- 20090211
LR  - 20081216
IS  - 1439-4413 (Electronic)
IS  - 0012-0472 (Linking)
VI  - 133 Suppl 8
DP  - 2008 Dec
TI  - [Arterial hypertension and cardiac arrhythmias].
PG  - S261-5
LID - 10.1055/s-0028-1100958 [doi]
AB  - VENTRICULAR ARRHYTHMIAS: Different factors--like hypertrophy, fibrosis, ischemia 
      and apoptosis increase the risk of ventricular arrhythmias and sudden arrhythmic 
      death. ACE inhibitors and Angiotensin receptor antagonists offer a curative 
      therapeutic approach. Beta-blocker are strongly recommended. Amiodarone may be 
      used for symptomatic arrhythmia suppression--but with no proven favourable 
      prognostic effect. The use of class-1 antiarrhythmic drugs is obsolete in the 
      presence of left ventricular hypertrophy and heart failure. Implantable 
      cardioverter/defibrillators (ICD) have been proven to have a positive effect on 
      survival in secondary and primary prevention of sudden cardiac death, and so has 
      cardiac synchronization in severe cardiac dysfunction and widened QRS complex. 
      Atrial fibrillation (AF): Arterial hypertension represents the main risk factor 
      for AF. Patients' age, left ventricular hypertrophy, left atrial dilatation and 
      angiotensin-II activation play an important role in the induction and maintenance 
      of AF. Angiotensin-receptor and beta-blockers seem to be efficacious in AF 
      suppression and also on the regression of hypertrophy. The use of antiarrhythmic 
      agents (AA) is limited because of their relatively low long-term efficacy and 
      pro-arrhythmia properties. Best results may be achieved with class 1C AA drugs in 
      patients with no or minimal structural heart disease. In all other cases 
      amiodarone is suitable but is limited by its side effects. In patients with no or 
      only a few symptoms rate control may be sufficient, but if there are symptoms 
      interventional left atrial ablation of pulmonary veins should be attempted as a 
      real curative strategy.
FAU - Vester, E G
AU  - Vester EG
AD  - Abteilung Kardiologie, Evangelisches Krankenhaus Dusseldorf, Dusseldorf. 
      kardiologie@evk-duesseldorf.de
LA  - ger
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Hochdruck und Herzrhythmusstorungen.
DEP - 20081215
PL  - Germany
TA  - Dtsch Med Wochenschr
JT  - Deutsche medizinische Wochenschrift (1946)
JID - 0006723
RN  - 0 (Adrenergic beta-Antagonists)
RN  - 0 (Angiotensin II Type 1 Receptor Blockers)
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Anti-Arrhythmia Agents)
SB  - IM
MH  - Adrenergic beta-Antagonists/therapeutic use
MH  - Angiotensin II Type 1 Receptor Blockers/therapeutic use
MH  - Angiotensin-Converting Enzyme Inhibitors/therapeutic use
MH  - Animals
MH  - Anti-Arrhythmia Agents/therapeutic use
MH  - Apoptosis
MH  - Arrhythmias, Cardiac/*etiology/prevention & control/therapy
MH  - Atrial Flutter/epidemiology/physiopathology/therapy
MH  - Catheter Ablation
MH  - Death, Sudden, Cardiac/etiology/prevention & control
MH  - Defibrillators, Implantable
MH  - Electric Countershock
MH  - Heart/physiopathology
MH  - Humans
MH  - Hypertension/*complications/therapy
MH  - Hypertrophy, Left Ventricular/complications/etiology/therapy
MH  - Myocardium/pathology
MH  - Risk Factors
RF  - 25
EDAT- 2008/12/17 09:00
MHDA- 2009/02/12 09:00
CRDT- 2008/12/17 09:00
PHST- 2008/12/17 09:00 [entrez]
PHST- 2008/12/17 09:00 [pubmed]
PHST- 2009/02/12 09:00 [medline]
AID - 10.1055/s-0028-1100958 [doi]
PST - ppublish
SO  - Dtsch Med Wochenschr. 2008 Dec;133 Suppl 8:S261-5. doi: 10.1055/s-0028-1100958. 
      Epub 2008 Dec 15.